

MANAGEMENT TEAM

Lewis (Rusty) Williams, MD, PhD
Executive Chairman and Founder
Julia P. Gregory
President and CEO
W. Michael Kavanaugh, MD
Sr. VP Research and Development
Kevin Baker, PhD
VP Pre-Clinical Development
Marc Belsky
VP Finance
Lauretta Cesario
VP Human Resources
Jeff Finer, MD, PhD
VP Discovery
Harold Keer, MD, PhD
VP Clinical Development
Aron Knickerbocker
VP Business Development
Bart Wise, PhD, JD
VP Intellectual Property
Brian Wong, MD, PhD
VP Immunology and Discovery

BOARD OF DIRECTORS

Brian Atwood
Versant Ventures
Jim Blair, PhD
Domain Associates
Brook Byers
Kleiner Perkins Caufield Byers
Fred Cohen, MD, D. Phil
TPG Ventures
Lee Douglas
Co-founder, Cor Therapeutics
Julia P. Gregory
President and CEO
Mark McDade
COO and EVP Global Oprns, UCB SA
Lewis (Rusty) Williams, MD, PhD
Executive Chairman and Founder

SCIENTIFIC ADVISORY BOARD

Stanley Cohen, MD
Stanford University Medical Center
Joseph Goldstein, MD
UT Southwestern Medical School
C. Ronald Kahn, MD
Joslin Diabetes Center
Harvard Medical School
Robert Lefkowitz, MD
Duke University Medical Center
Ronald Levy, MD
Stanford University Medical Center
Daniel Von Hoff, MD
Translational Genomics Research Inst
Arthur Weiss, MD, PhD
UC San Francisco


Employees: 115

PROTEIN MEDICINES FOR LIFE


Five Prime Therapeutics, Inc. is a clinical-stage biotech company discovering innovative protein and antibody therapeutics using its world-class discovery engine. We are building a strong pipeline of first-in-class biologics that currently includes an oncology product in a phase 1 trial and multiple preclinical and research programs in oncology, metabolic disease and immunology. We use our unique discovery platform to comprehensively screen secreted proteins and receptors using novel cell-based and in vivo screening systems. FivePrime is in a strong financial position, having raised approximately \$190M to date from equity investments and through collaborations with major pharmaceutical companies.

PRODUCTS

FP-1039 is a first-in-class and potentially best-in-class biologic targeting the FGF/FGFR pathway in cancer. FP-1039 is a soluble fusion protein designed to neutralize the activity of multiple FGFs and FGF receptors. Tumors of the breast, prostate, lung, ovary, colon and pancreas have been reported to have a strong dependence upon the FGF/FGFR pathway for survival and growth. Clinically, activation of this pathway has been correlated with both decreased survival and time to metastasis in several major cancers and escape from anti-VEGF therapy in patients. A Phase 1 study in advanced solid tumor cancers is underway to test safety and tolerability. Preliminary clinical data from this study were presented at the AACR-NCI-EORTC Conference in November 2009. Further clinical development plans will be presented at ASCO in June 2010.



PIPELINE & THERAPEUTIC PROGRAMS



UNIQUE DISCOVERY ENGINE

FivePrime's proven biologics discovery engine is the industry's most comprehensive platform for interrogating the extracellular proteome. FivePrime's proprietary, comprehensive, high-quality and validated library of all human secreted proteins, extracellular domains of receptors and peptides is the foundation of this engine and currently includes more than 4,000 proteins and peptides.

This unprecedented library is queried using three powerful platforms to identify novel biologic product candidates and antibody targets rapidly:

1. High-content cell-based screening assays designed to model disease states, using primary cells and employing upwards of 30 readouts in a single well.
2. Proprietary RIPPSSM (Rapid In Vivo Protein Production System) for interrogation of complex biological and medically important systems in animals.
3. Proprietary Ligand/Receptor matching platform to rapidly de-orphanize therapeutically important proteins.

PARTNERING

FivePrime is currently collaborating with Pfizer to discover innovative biologics in the fields of oncology and diabetes.

FivePrime is currently seeking development and commercialization partners for FP-1039, FP-1069, and drug discovery programs in cardiovascular, skeletal muscle, obesity, respiratory and autoimmune diseases.

For inquiries please contact us at: business.development@fiveprime.com